REPROCELL
Tiana Hill is a Research Technologist at REPROCELL since December 2022, where extensive collaboration on critical research initiatives involves investigating therapeutic compound effects on various diseases while ensuring compliance with study requirements and regulatory standards. Prior to this role, Tiana served as a Graduate Research Assistant at Morehouse School of Medicine from June 2020 to April 2022, leading a pioneering neurobiology research project focused on neuroconversion and stem cell research, utilizing literature reviews and advanced microscopy techniques. Educational achievements include a Master's degree in Neuroscience from Morehouse School of Medicine and a Bachelor of Science in Biology (Pre Med) from Spelman College.
This person is not in any offices
REPROCELL
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES/ iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.